Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · IEX Real-Time Price · USD
2.020
+0.090 (4.66%)
May 2, 2024, 11:59 AM EDT - Market open
Amylyx Pharmaceuticals Revenue
In the year 2023, Amylyx Pharmaceuticals had annual revenue of $380.79M with 1,612.94% growth. Revenue in the quarter ending December 31, 2023 was $108.45M with 395.54% year-over-year growth.
Revenue (ttm)
$380.79M
Revenue Growth
+1,612.94%
P/S Ratio
0.34
Revenue / Employee
$991,630
Employees
384
Market Cap
137.39M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| So-Young International | 211.29M |
| Outset Medical | 130.38M |
| Repare Therapeutics | 51.13M |
| Augmedix | 44.86M |
| Seer, Inc. | 16.66M |
| DBV Technologies | 15.73M |
| MSP Recovery | 7.71M |
| Omega Therapeutics | 3.09M |
AMLX News
- 3 hours ago - Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 22 days ago - Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome - Business Wire
- 22 days ago - April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLX - Accesswire
- 23 days ago - Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX - Accesswire
- 23 days ago - Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline - Accesswire
- 23 days ago - FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm - Accesswire
- 23 days ago - The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX - PRNewsWire
- 23 days ago - Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - Accesswire